Susquehanna International Group’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-375
| Closed | -$9.99K | – | 13588 |
|
|
2023
Q4 | $9.99K | Sell |
375
-22
| -6% | -$911 | ﹤0.01% | 12073 |
|
|
2023
Q3 | $24K | Sell |
397
-334
| -46% | -$31.3K | ﹤0.01% | 11556 |
|
|
2023
Q2 | $74.4K | Sell |
731
-552
| -43% | -$76K | ﹤0.01% | 11143 |
|
|
2023
Q1 | $227K | Sell |
1,283
-609
| -32% | -$204K | ﹤0.01% | 10327 |
|
|
2022
Q4 | $731K | Sell |
1,892
-44
| -2% | -$16.7K | ﹤0.01% | 6903 |
|
|
2022
Q3 | $652K | Buy |
1,936
+1,330
| +219% | +$482K | ﹤0.01% | 7749 |
|
|
2022
Q2 | $199K | Sell |
606
-1,352
| -69% | -$474K | ﹤0.01% | 10643 |
|
|
2022
Q1 | $857K | Buy |
1,958
+1,125
| +135% | +$462K | ﹤0.01% | 7531 |
|
|
2021
Q4 | $365K | Sell |
833
-5,898
| -88% | -$2.96M | ﹤0.01% | 10010 |
|
|
2021
Q3 | $3.74M | Buy |
6,731
+4,370
| +185% | +$2.19M | ﹤0.01% | 4488 |
|
|
2021
Q2 | $1.21M | Sell |
2,361
-1,547
| -40% | -$980K | ﹤0.01% | 7216 |
|
|
2021
Q1 | $3.06M | Sell |
3,908
-1,517
| -28% | -$1.04M | ﹤0.01% | 4908 |
|
|
2020
Q4 | $2.96M | Buy |
5,425
+439
| +9% | +$230K | ﹤0.01% | 4335 |
|
|
2020
Q3 | $2.28M | Sell |
4,986
-2,300
| -32% | -$1.34M | ﹤0.01% | 4367 |
|
|
2020
Q2 | $4.49M | Buy |
7,286
+3,089
| +74% | +$1.71M | ﹤0.01% | 3152 |
|
|
2020
Q1 | $2M | Sell |
4,197
-3,906
| -48% | -$2.12M | ﹤0.01% | 3968 |
|
|
2019
Q4 | $4.7M | Buy |
8,103
+1,675
| +26% | +$1.18M | ﹤0.01% | 3047 |
|
|
2019
Q3 | $4.23M | Sell |
6,428
-8,044
| -56% | -$6.69M | ﹤0.01% | 2953 |
|
|
2019
Q2 | $11.2M | Buy |
14,472
+9,341
| +182% | +$6.56M | ﹤0.01% | 1780 |
|
|
2019
Q1 | $3.62M | Buy |
5,131
+4,373
| +577% | +$2.62M | ﹤0.01% | 2880 |
|
|
2018
Q4 | $355K | Sell |
758
-3,273
| -81% | -$2.11M | ﹤0.01% | 6701 |
|
|
2018
Q3 | $3.48M | Sell |
4,031
-4,194
| -51% | -$3.03M | ﹤0.01% | 3157 |
|
|
2018
Q2 | $5.67M | Buy |
8,225
+4,081
| +98% | +$2.07M | ﹤0.01% | 2558 |
|
|
2018
Q1 | $1.85M | Buy |
4,144
+2,497
| +152% | +$1.21M | ﹤0.01% | 4060 |
|
|
2017
Q4 | $726K | Sell |
1,647
-3,939
| -71% | -$1.8M | ﹤0.01% | 5874 |
|
|
2017
Q3 | $2.75M | Sell |
5,586
-3,861
| -41% | -$1.93M | ﹤0.01% | 3363 |
|
|
2017
Q2 | $5.23M | Buy |
9,447
+1,764
| +23% | +$1.12M | ﹤0.01% | 2354 |
|
|
2017
Q1 | $5.09M | Buy |
7,683
+5,622
| +273% | +$3M | ﹤0.01% | 2337 |
|
|
2016
Q4 | $689K | Buy |
+2,061
| New | +$661K | ﹤0.01% | 6317 |
|
|
2016
Q2 | – | Sell |
-344
| Closed | -$77K | – | 9466 |
|
|
2016
Q1 | $77K | Sell |
344
-50
| -13% | -$14.9K | ﹤0.01% | 8529 |
|
|
2015
Q4 | $239K | Sell |
394
-417
| -51% | -$229K | ﹤0.01% | 8121 |
|
|
2015
Q3 | $417K | Buy |
+811
| New | +$543K | ﹤0.01% | 7445 |
|
Other funds holding TVRD
FCM
Susquehanna International Group's TVRD Position: Q1 2025 in Review
Susquehanna International Group sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 39,262 shares — an estimated $721K sold.
Susquehanna International Group first reported a position in TVRD in Q4 2014 and held it in 37 quarters. The position peaked at $18.4M in Q1 2017. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.
- Susquehanna International Group reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
- Susquehanna International Group sold 39,262 Tvardi Therapeutics shares in Q1 2025, an estimated $721K.
- Susquehanna International Group first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 37 quarters.
- Susquehanna International Group's Tvardi Therapeutics position peaked at $18.4M in Q1 2017.
- 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.